Axsome Therapeutics (AXSM) Current Assets (2021 - 2026)
Axsome Therapeutics' Current Assets history spans 6 years, with the latest figure at $611.2 million for Q1 2026.
- On a quarterly basis, Current Assets rose 23.57% to $611.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $611.2 million, a 23.57% increase, with the full-year FY2025 number at $589.0 million, up 21.42% from a year prior.
- Current Assets hit $611.2 million in Q1 2026 for Axsome Therapeutics, up from $589.0 million in the prior quarter.
- Over the last five years, Current Assets for AXSM hit a ceiling of $611.2 million in Q1 2026 and a floor of $86.8 million in Q1 2022.
- Historically, Current Assets has averaged $424.3 million across 5 years, with a median of $485.1 million in 2024.
- Biggest five-year swings in Current Assets: skyrocketed 399.81% in 2023 and later dropped 10.9% in 2024.
- Tracing AXSM's Current Assets over 5 years: stood at $245.6 million in 2022, then skyrocketed by 105.28% to $504.3 million in 2023, then fell by 3.81% to $485.1 million in 2024, then rose by 21.42% to $589.0 million in 2025, then grew by 3.77% to $611.2 million in 2026.
- Business Quant data shows Current Assets for AXSM at $611.2 million in Q1 2026, $589.0 million in Q4 2025, and $565.3 million in Q3 2025.